pipeline-prospector-insert-v1
X

Find Drugs for Genetic Disease in Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Isotretinoin

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Timber Pharmaceuticals

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Merger January 28, 2020

            Details:

            Under the terms of the merger agreement, a wholly-owned subsidiary of BioPharmX will be merged with and into Timber, with Timber surviving the merger as a wholly-owned subsidiary of BioPharmX.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trehalose API

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            Seelos seeks scientific advice and protocol assistance for a European clinical study of SLS-005 in patients with Sanfillipo syndrome type A and B from EMA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ELX-02

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2020

            Details:

            Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IPI-549,Nivolumab,Atezolizumab

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: BVF Partners L.P

            Deal Size: $71.5 million Upfront Cash: Undisclosed

            Deal Type: Financing January 09, 2020

            Details:

            The funds will be used for all ongoing IPI-549 clinical trials through key data readouts.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MS1819,Pancreatic enzyme replacement therapy

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD with standard PERT.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-007

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50%.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PTG-300

            Therapeutic Area: Genetic Disease

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2020

            Details:

            This Phase 2 study of PTG-300 in hereditary hemochromatosis is an open label, multicenter study designed to evaluate the effects of PTG-300 over 24 weeks of treatment.